Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.48 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | IKBKB | O14920 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19834409 | 0.83 | NPC1 (0.49) | KDM4EALDH1A1HPGDMAP4K4NOTUM | |
| SCHEMBL29183431 | 0.82 | ALDH1A1 (0.51) | KDM4EALDH1A1HPGDNOTUMNPC1 | |
| SCHEMBL29183388 | 0.82 | NPC1 (0.48) | KDM4EALDH1A1HPGDNPC1RAB9A | |
| SCHEMBL9259362 | 0.82 | ALOX15 (0.55) | KDM4EALDH1A1HPGDNPC1RAB9A | |
| SCHEMBL28128556 | 0.82 | NPC1 (0.50) | KDM4EALDH1A1HPGDNOTUMNPC1 | |
| SCHEMBL7450038 | 0.81 | ALOX15 (0.53) | KDM4EALDH1A1HPGDNOTUMNPC1 | |
| SCHEMBL15062653 | 0.80 | NPC1 (0.47) | KDM4EALDH1A1HPGDNPC1RAB9A | |
| SCHEMBL29183414 | 0.78 | KDM4E (0.55) | KDM4EALDH1A1HPGDNOTUMNPC1 | |
| SCHEMBL27330485 | 0.77 | ALDH1A1 (0.42) | ALDH1A1HPGDNPC1RAB9ATP53 | |
| SCHEMBL22042129 | 0.74 | NOTUM (0.50) | NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270202-A1 | SUBSTITUTED 4-AMINOISOINDOLINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2025-08-28 | — | — | US | disclosed |
| EP-4545524-A1 | SUBSTITUTED 4-AMINOISOINDOLINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2025-04-30 | — | — | EP | disclosed |
| WO-2023246944-A1 | SUBSTITUTED 4-AMINOISOINDOLINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 中国科学院上海药物研究所 | 2023-12-28 | — | — | WO | disclosed |
| CN-117285524-A | Substituted 4-amino isoindoline compounds, preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2023-12-26 | — | — | CN | disclosed |
| US-9789089-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-9789089-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-9789089-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| EP-2943487-B1 | 5-MEMBERED HETEROARYLS AND THEIR USE AS ANTIVIRAL AGENTS | GILEAD SCIENCES INC (US) | 2016-11-16 | — | — | EP | disclosed |
| EP-2943487-B1 | 5-MEMBERED HETEROARYLS AND THEIR USE AS ANTIVIRAL AGENTS | GILEAD SCIENCES INC (US) | 2016-11-16 | — | — | EP | disclosed |
| US-20160067224-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-03-10 | — | — | US | disclosed |
| US-20160067224-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-03-10 | — | — | US | disclosed |
| US-20160067224-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-03-10 | — | — | US | disclosed |
| US-9220710-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-9220710-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-9220710-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| EP-2943487-A1 | 5-MEMBERED HETEROARYLS AND THEIR USE AS ANTIVIRAL AGENTS | Gilead Sciences, Inc. (US) | 2015-11-18 | — | — | EP | disclosed |
| US-20140221421-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221421-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221421-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| WO-2014110298-A1 | 5-MEMBERED HETEROARYLS AND THEIR USE AS ANTIVIRAL AGENTS | GILEAD SCIENCES, INC. (US) | 2014-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160067224-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, G6PD | KDM4E 4478/4885ALDH1A1 372/4885HPGD 816/4885 |
| US-20250270202-A1 | SUBSTITUTED 4-AMINOISOINDOLINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | CUL4B, CUL3, CUL4A | KDM4E 238/4885ALDH1A1 794/4885HPGD 3356/4885 |
| US-20140221421-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, G6PD | KDM4E 4478/4885ALDH1A1 372/4885HPGD 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.